113 related articles for article (PubMed ID: 30008379)
21. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.
Liu L; Chen B; Qin S; Li S; He X; Qiu S; Zhao W; Zhao H
Biochem Biophys Res Commun; 2010 Feb; 392(2):190-5. PubMed ID: 20060381
[TBL] [Abstract][Full Text] [Related]
22. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
Warren KE; McCully C; Dvinge H; Tjørnelund J; Sehested M; Lichenstein HS; Balis FM
Cancer Chemother Pharmacol; 2008 Aug; 62(3):433-7. PubMed ID: 17960383
[TBL] [Abstract][Full Text] [Related]
23. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
24. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
[TBL] [Abstract][Full Text] [Related]
25. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.
Stapleton SL; Thompson PA; Ou CN; Berg SL; McGuffey L; Gibson B; Blaney SM
Cancer Chemother Pharmacol; 2008 Apr; 61(4):647-52. PubMed ID: 17541590
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of CD22 by Chidamide promotes CAR T cells functionality.
Yang X; Yu Q; Xu H; Zhou J
Sci Rep; 2021 Oct; 11(1):20637. PubMed ID: 34667217
[TBL] [Abstract][Full Text] [Related]
27. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China.
Lu X; Ning Z; Li Z; Cao H; Wang X
Intractable Rare Dis Res; 2016 Aug; 5(3):185-91. PubMed ID: 27672541
[TBL] [Abstract][Full Text] [Related]
28. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
[TBL] [Abstract][Full Text] [Related]
29. [Inducing effect of chidamide on apoptosis of multiple myeloma cells and its relerance to DNA damage response].
Xu L; Tang HL; Gong X; Xin XL; Dong Y; Gao GX; Shu MM; Chen XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):450-4. PubMed ID: 25948203
[TBL] [Abstract][Full Text] [Related]
30. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
Lun Y; Yang JJ; Wu Y
J Clin Pharm Ther; 2017 Dec; 42(6):786-789. PubMed ID: 28646565
[TBL] [Abstract][Full Text] [Related]
31. HPLC-APCI-MS/MS method for the determination of catalpol in rat plasma and cerebrospinal fluid: application to an in vivo pharmacokinetic study.
Wang Q; Xing M; Chen W; Zhang J; Qi H; Xu X
J Pharm Biomed Anal; 2012 Nov; 70():337-43. PubMed ID: 22677654
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC-MS/MS: application for a pharmacokinetic study.
Thappali SR; Varanasi KV; Veeraraghavan S; Vakkalanka SK; Mukkanti K
J Mass Spectrom; 2012 Dec; 47(12):1612-9. PubMed ID: 23280750
[TBL] [Abstract][Full Text] [Related]
33. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
Zhuang Y; Fraga CH; Hubbard KE; Hagedorn N; Panetta JC; Waters CM; Stewart CF
Cancer Res; 2006 Dec; 66(23):11305-13. PubMed ID: 17145877
[TBL] [Abstract][Full Text] [Related]
34. Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling.
Shin BS; Bulitta JB; Balthasar JP; Kim M; Choi Y; Yoo SD
Cancer Chemother Pharmacol; 2011 Aug; 68(2):465-75. PubMed ID: 21069337
[TBL] [Abstract][Full Text] [Related]
35. Determination of HS270, a new histone deacetylase inhibitor, in rat plasma by LC-MS/MS--application to a preclinical pharmacokinetic study.
Zhong GP; Chen JY; Bi HC; Qin XL; Dai CL; Liu J; Chen X; Zeng GX; Huang ZY; Huang M
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Nov; 879(30):3452-8. PubMed ID: 21983196
[TBL] [Abstract][Full Text] [Related]
36. A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China.
Liu W; Zhao D; Liu T; Niu T; Song Y; Xu W; Jin J; Cai Q; Huang H; Li Z; Hou M; Zhang H; Zhou J; Hu J; Shen J; Shi Y; Yang Y; Zhang L; Zhao W; Ding K; Qiu L; Tan H; Zhang Z; Liu L; Wang J; Xu B; Zhou H; Gao G; Xue H; Bai O; Feng R; Huang X; Yang H; Yan X; Zeng Q; Liu P; Li W; Mao M; Su H; Wang X; Xu J; Zhou D; Zhang H; Ma J; Shen Z; Zhu J
Front Oncol; 2021; 11():750323. PubMed ID: 34804937
[TBL] [Abstract][Full Text] [Related]
37. Chidamide in the treatment of peripheral T-cell lymphoma.
Chan TS; Tse E; Kwong YL
Onco Targets Ther; 2017; 10():347-352. PubMed ID: 28138258
[TBL] [Abstract][Full Text] [Related]
38. Comparative pharmacokinetics of tedizolid in rat plasma and cerebrospinal fluid.
Gu L; Ma M; Zhang Y; Zhang L; Zhang S; Huang M; Zhang M; Xin Y; Zheng G; Chen S
Regul Toxicol Pharmacol; 2019 Oct; 107():104420. PubMed ID: 31295511
[TBL] [Abstract][Full Text] [Related]
39. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells.
Gong K; Xie J; Yi H; Li W
Biochem J; 2012 May; 443(3):735-46. PubMed ID: 22339555
[TBL] [Abstract][Full Text] [Related]
40. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
